Medicine Supply Notification: Reboxetine (Edronax®) 4mg tablets
Department of Health and Social Care (DHSC) has issued a medicine supply notification for Reboxetine (Edronax®) 4mg tablets.
MSN/2023/073
Tier 2 – medium impact
Date of issue 31st July 2023
- Reboxetine (Edronax®) 4mg tablets are out of stock from mid-August until the end of October 2023.
- Unlicensed imported stock is available (see details below)
- If local stock holding, imported stock and mutual aid cannot meet anticipated demand until the resupply date, alternative antidepressants with noradrenergic properties should be considered.
Unlicensed imports
The following specialist importer has confirmed they can source unlicensed Reboxetine 4mg tablets. (please note there may be other companies that can also source supplies):
If there is currently no listing on dm+d for the imported product for prescribers to select using their prescribing systems an EPS prescription for unlicensed Reboxetine 4mg tablets cannot be issued. Where a prescriber wishes to prescribe a specially manufactured or imported product, an FP10 paper prescription should be issued as ‘ Reboxetine 4mg tablets (Special Order)‘ and endorsed by the pharmacy as a non-Part VIIIB special with the following information:
- Amount dispensed over pack size used;
- Invoice price per pack size from which the order was supplied less any discount or rebate;
- Manufacturers’/importers’ MHRA licence number;
- Batch number of the product supplied;
- SP
A copy of this medicine supply notification, including further information, has been sent to all pharmacy NHS email addresses.
DHSC and NHSE/I have now launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. The contents of these MSNs can now be viewed on the Tool.
The Tool also details any changes to resupply dates and updates to the entries.
To access the Tool you will need an NHS email address. Once set up and logged in, you will be able to access it online.
New shortages not listed on the SPS website, can be reported using our shortage reporting tool.
